Colorectal cancer heavyweight news! Mercadon Keytruda first-line treatment of MSI-H/dMMR patients head-to-head Phase III clinical efficacy beats standard chemotherapy!

, , 2020 /PRNewswire
BIOON/ -- Merck and Co recently announced the evaluation of the first-line treatment of the anti-PD-1 therapy Keytruda (Korida, generic name: pembrolizumab, Pablo Zumab, Pablo Zuma) The phase III KEYNOTE-177 trial (NCT02563002) in patients with high satellite instability (MSI-H) or mismatch repair defects (dMMR), non-rectructive or metastatic colorectal cancer (mCRC) reached one of the two main endpoints of no progression (PFS) a mid-term analysis conducted by the Independent Data Monitoring Committee (DMC) found that in this patient population, Keytruda monotherapy achieved a statistically significant and clinically significant improvement in PFS compared to chemotherapy (mFOLFOX or FOLFIRI, combined or not associated with bebamaror monoantigen or citoshiproanoids selected by the researchers) In accordance with the DMC's recommendations, the study will continue without any changes to assess the total lifetime (OS) of one of the two main endpoints In this experiment, Keytruda's safety was consistent with previously reported studies and no new safety signals were found it is worth mentioning that KEYNOTE-117 is the first head-to-head phase III trial that compares single anticancer drugs with standard nursing chemotherapy for first-line treatment of MSI-H or dMMR colorectal cancer The data from the study will be presented at the upcoming medical conference and will be shared with regulators around the world "Keytruda's head-to-head data is the first time that a single-drug anticancer formulation -- especially anti-PD-1 monotherapy -- has shown a significant improvement in the treatment of MSI-H colorectal cancer patients compared to chemotherapy, including the current standard mFOLFOX6-Bevado monoantigen treatment," said Dr Roy Bayne, Chief Medical Officer, Senior Vice President and Head of Global Clinical Development, 's Mercadon Research Laboratory These data in a first-line treatment environment further demonstrate the benefits of Keytruda monotherapy for MSI-H or dMMR tumor patients We look forward to sharing this data with the medical community and regulators as soon as possible "
May 2017, Keytruda was approved by the U.S FDA , becoming the first anticancer drug based on MSI-H/dMMR biomarker to treat patients with MSI-H or dMMR solid tumors, regardless of the type of tumor colorectal cancer (CRC) is a cancer with a disease in the color or rectum, which is part of the body's digestive or gastrointestinal system CRC is the third most common cancer in the world and the second leading cause of cancer-related death It is estimated that nearly 850,000 new cases of CRC have been confirmed globally and more than 880,000 deaths have been confirmed worldwide in 2018 In the United States, 105,000 new cases of colon cancer and 43,000 new cases of rectal cancer are expected to be confirmed in the United States, and 53,000 people are expected to die from colorectal cancer The five-year survival rates for advanced/metastatic colon and rectal cancer (phase IV) were 14% and 15%, respectively microsatellite instability (MSI) is a change in the DNA of certain cells, such as tumor cells, defined by the National Cancer Institute (NCI), in which the number of repetitions (short, repeated DNA sequences) of microsatellites is different from the number of repetitions in DNA during genetic The cause of microsatellite instability may be a flawed ability to repair errors when copying DNA in cells This defect is also known as mismatch repair defect (dMMR) It is estimated that about 10-15% of CRC patients tumor rated MSI-H or dMMR when tested dMMR or MSI-H mCRC patients are less likely to benefit from routine chemotherapy regimens, often with poor prognosis and low survival rates Therefore, all CRC patients should be routinely examined for dMMR or MSI-H status Keytruda is a PD-(L)1 tumor immunotherapy that helps detect and fight tumor cells by improving the body's immune system Keytruda is a human-derived monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, activating T lymphocytes that may affect tumor cells and healthy cells so far, several PD-1
1-
oncology immunotherapy have been approved worldwide, with Keytruda being the leader in the field, with more than 20 therapeutic indications approved, and global sales reaching $11.1 billion in 2019, up 58% from the previous year with the largest clinical development of immuno-oncology in the industry, Mersadon, there are more than 1,000 clinical trials investigating Keytruda's role in multiple types of tumor and treatment background The Keytruda Clinical Project aims to understand the role of the drug in cancer and the factors that may predict patients will benefit from Keytruda treatment, including exploring several different biomarker (biovalleybioon.com) original origin: AnnounceMerck KEYTRUDA® (pembrolizumab) Ofly Improved Progreion-Free Survival a Firt-Line Care For Microatellite Intage-High (MSI-H) or Mimatch Repair Deficient (dMMR) Colorectal cancer